Enliven (ELVN) Insider Sale of $345,000 Amid 130% Stock Surge

Lori Anne Kunkel, Director of Enliven Therapeutics (NASDAQ:ELVN), sold 10,000 shares for approximately $345,000 on June 5, 2026, at a weighted average price of $34.54. This transaction marked Kunkel's first open-market sale, representing 16% of her direct holdings, reducing her shares from 61,884 to 51,884. At the time, ELVN shares returned 62.4% over the past year, closing at $34.71 on the transaction date before appreciating to $50 by the following Friday. The sale was executed under a Rule 10b5-1 trading plan set on March 6, 2026, amid strong market performance for the firm’s oncology therapeutics.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.